


Supplementary Figure S2. PRISMA flow diagram of the literature search



Supplementary Figure S3A. Risk of bias summary


	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Cookson 1987	?	?	+	+	?	-	-
Faraone 1989	?	?	+	+	?	-	-
Hirschowitz 1997	?	?	+	+	+	+	+
Hogarty 1988	?	?	+	+	-	-	-
Hogarty 1995	?	?	+	+	?	-	-
Inderbitzin 1994	-	?	+	+	+	+	+
Johnson 1987	+	?	+	+	?	+	-
Kane 1983	?	?	+	+	?	-	+
Kinion 2000	?	?	-	+	?	?	?
Newcomer 1992	?	?	+	+	+	-	-
Rouillon 2008	+	+	-	-	+	+	-
Schooler 1997	?	?	+	+	?	-	-
Takeuchi 2013	?	+	-	-	+	+	+
Uchida 2006	+	?	-	-	+	+	?
Volavka 2000	?	?	+	+	+	+	+
Wang 2010	+	+	-	-	+	+	-
Yamanouchi 2014	+	+	-	-	+	+	+
Zhou 2018	+	?	-	+	+	+	+

Note: +, low risk of bias; -, high risk of bias; ?, questionable risk of bias


Supplementary Figure S3B. Funnel plot: Overall patients

1. Relapse/Hospitalization

1.1 Relapse (primary outcome)




1.2 Hospitalization




2. Study discontinuation


2.1 Study discontinuation due to all causes



2.2 Study discontinuation due to inefficacy




2.3 Study discontinuation due to intolerability




3. Psychopathology


3.1 Total score




3.2 Positive symptom



3.3 Negative symptom




3.4 CGI-S




4. Adverse effects


4.1 SAS




4.2 BAS




4.3 AIMS




4.4 DIEPSS




4.5 Body Weight



4.6 Neurocognitive Measures



4.7 QOL




Abbreviations: AIMS, Abnormal Involuntary Movement Scale; BARS, Barnes Akathisia Rating Scale; CGI-S, Clinical Global Impressions – Severity scale; DIEPSS, Drug-Induced Extrapyramidal Symptoms Scale; QOL, quality of life; SAS, Simpson Angus Scale


Supplementary Figure S3C. Funnel plot: Subgroup analysis, antipsychotic dose after reduction

1. Relapse/Hospitalization

1.1 Relapse (primary outcome)




1.2 Hospitalization




2. Study discontinuation


2.1 Study discontinuation due to all causes



2.2 Study discontinuation due to inefficacy




2.3 Study discontinuation due to intolerability




3. Psychopathology


3.1 Total score




3.2 Positive symptom



3.3 Negative symptom




3.4 CGI-S




4. Adverse effects


4.1 SAS




4.2 BAS




4.3 AIMS




4.4 DIEPSS




4.5 Body Weight



4.6 Neurocognitive Measures



4.7 QOL



Abbreviations: AIMS, Abnormal Involuntary Movement Scale; BARS, Barnes Akathisia Rating Scale; CGI-S, Clinical Global Impressions – Severity scale; DIEPSS, Drug-Induced Extrapyrimal Symptoms Scale; QOL, quality of life; SAS, Simpson Angus Scale